Literature DB >> 12860416

Identification of a novel Ezrin-binding site in syndecan-2 cytoplasmic domain.

Francesc Granés1, Christine Berndt, Christian Roy, Paul Mangeat, Manuel Reina, Senén Vilaró.   

Abstract

ERM (Ezrin/Radixin/Moesin) proteins are crosslinkers between plasma membrane proteins and the actin cytoskeleton, thereby involved in the formation of cell adhesion sites. Earlier work showed that Ezrin links syndecan-2 to the actin cytoskeleton. Here we provide evidence that the Ezrin N-terminal domain binds to the syndecan-2 cytoplasmic domain with an estimated K(D) of 0.71 microM and without the requirement of other proteins. We also studied the regions in the syndecan-2 cytoplasmic domain implicated in the binding to Ezrin. By truncating the syndecan-2 cytoplasmic domain and by oligopeptide competition assays we show that the Ezrin-binding sequence is not located in the positively charged juxtamembrane region (RMRKK), but in the neighboring sequence DEGSYD. We therefore conclude that the consensus sequence for Ezrin binding is unique among membrane proteins, suggesting a distinct regulation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12860416     DOI: 10.1016/s0014-5793(03)00712-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  19 in total

Review 1.  Ezrin/radixin/moesin proteins and Rho GTPase signalling in leucocytes.

Authors:  Aleksandar Ivetic; Anne J Ridley
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

2.  The cardiac syndecan-4 interactome reveals a role for syndecan-4 in nuclear translocation of muscle LIM protein (MLP).

Authors:  Sabrina Bech Mathiesen; Marianne Lunde; Jan Magnus Aronsen; Andreas Romaine; Anita Kaupang; Marita Martinsen; Gustavo Antonio de Souza; Tuula A Nyman; Ivar Sjaastad; Geir Christensen; Cathrine Rein Carlson
Journal:  J Biol Chem       Date:  2019-04-09       Impact factor: 5.157

3.  Molecular mediators for raft-dependent endocytosis of syndecan-1, a highly conserved, multifunctional receptor.

Authors:  Keyang Chen; Kevin Jon Williams
Journal:  J Biol Chem       Date:  2013-03-22       Impact factor: 5.157

4.  Syndecan-2 cytoplasmic domain up-regulates matrix metalloproteinase-7 expression via the protein kinase Cγ-mediated FAK/ERK signaling pathway in colon cancer.

Authors:  Bohee Jang; Hyejung Jung; Sojoong Choi; Young Hun Lee; Seung-Taek Lee; Eok-Soo Oh
Journal:  J Biol Chem       Date:  2017-08-16       Impact factor: 5.157

5.  Interactome analysis reveals ezrin can adopt multiple conformational states.

Authors:  Raghuvir Viswanatha; Jessica Wayt; Patrice Y Ohouo; Marcus B Smolka; Anthony Bretscher
Journal:  J Biol Chem       Date:  2013-10-22       Impact factor: 5.157

Review 6.  Targeting syndecan-1: new opportunities in cancer therapy.

Authors:  Zecheng Yang; Shuaitong Chen; Haoqiang Ying; Wantong Yao
Journal:  Am J Physiol Cell Physiol       Date:  2022-05-18       Impact factor: 5.282

Review 7.  Merlin and the ERM proteins--regulators of receptor distribution and signaling at the cell cortex.

Authors:  Andrea I McClatchey; Richard G Fehon
Journal:  Trends Cell Biol       Date:  2009-04-01       Impact factor: 20.808

8.  The HSPG syndecan is a core organizer of cholinergic synapses.

Authors:  Xin Zhou; Camille Vachon; Mélissa Cizeron; Océane Romatif; Hannes E Bülow; Maëlle Jospin; Jean-Louis Bessereau
Journal:  J Cell Biol       Date:  2021-07-02       Impact factor: 10.539

9.  Sarm1, a negative regulator of innate immunity, interacts with syndecan-2 and regulates neuronal morphology.

Authors:  Chiung-Ya Chen; Chia-Wen Lin; Chiung-Ying Chang; Si-Tse Jiang; Yi-Ping Hsueh
Journal:  J Cell Biol       Date:  2011-05-09       Impact factor: 10.539

10.  Syndecan-2 promotes perineural invasion and cooperates with K-ras to induce an invasive pancreatic cancer cell phenotype.

Authors:  Tiago De Oliveira; Ivane Abiatari; Susanne Raulefs; Danguole Sauliunaite; Mert Erkan; Bo Kong; Helmut Friess; Christoph W Michalski; Jörg Kleeff
Journal:  Mol Cancer       Date:  2012-04-03       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.